HYPERION DEFI, INC.
HYPERION DEFI, INC. (HYPD): 6 pipeline candidates · 1 upcoming catalyst · ~6 mo cash runway. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
5.6 months
D/E 0.20 · 11% dilution
Lead: Approved
6 candidates
1 upcoming, next in ~1853d
9 buys · 0 sells (180d)
A transparent, data-derived signal for HYPERION DEFI, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$47.4M
Cash
$7.4M
Quarterly Burn
$4.2M
Runway
5.6 mo
Revenue
$244K
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (6 candidates)
| Drug | Phase |
|---|---|
| clobetasol propionate ophthalmic suspension 0.05% | Approved |
| eyen-530 | Preclinical |
| microline | Phase 3 |
| micropine | Preclinical |
| mydcombi | Approved |
| optejet ufd | Preclinical |
Upcoming Catalysts (1)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
28
Total value held
$3.9M
| Holder | Shares | Value |
|---|---|---|
| morgan stanley | 237,986 | $821K |
| jane street group, llc | 128,280 | $443K |
| renaissance technologies llc | 115,641 | $399K |
| citadel advisors llc | 112,906 | $390K |
| vanguard capital management llc | 84,409 | $291K |
| blackrock, inc. | 81,108 | $280K |
| geode capital management, llc | 77,080 | $266K |
| oppenheimer & co inc | 64,268 | $222K |
| investment house llc | 51,875 | $179K |
| ubs group ag | 48,790 | $168K |
Showing top 10 of 28 institutional holders of HYPERION DEFI, INC.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in HYPERION DEFI, INC.'s pipeline?
HYPERION DEFI, INC. (HYPD) has 6 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is HYPERION DEFI, INC.'s lead drug candidate?
HYPERION DEFI, INC.'s most advanced tracked candidate is clobetasol propionate ophthalmic suspension 0.05% (Approved) for post-operative inflammation and pain after ocular surgery.
What is HYPERION DEFI, INC.'s next catalyst?
HYPERION DEFI, INC.'s next tracked catalyst is a Patent_Expiry event — "Patent/Exclusivity Expiry: MYDCOMBI" — expected July 15, 2031.
What is HYPERION DEFI, INC.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, HYPERION DEFI, INC. has approximately 5.6 months of cash runway.
What is HYPERION DEFI, INC.'s market capitalization?
HYPERION DEFI, INC.'s market capitalization is approximately $47.4M.
Get the full picture on HYPERION DEFI, INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.